Blood Res.  2013 Dec;48(4):235-236. 10.5045/br.2013.48.4.235.

Attempts to treat patients with hemophilia, the "royal disease"

• Park R

• KMID: 2172866
• DOI: http://doi.org/10.5045/br.2013.48.4.235

Abstract

No abstract available.

MeSH Terms

Hemophilia A*
Humans

Reference

1. Lawrence JS, Johnson JB. The presence of a circulating anticoagulant in a male member of a hemophiliac family. Trans Am Clin Climatol Assoc. 1941; 57:223–231. PMID: 21407643.

2. Darby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost. 2004; 2:1047–1054. PMID: 15219185.

3. Kempton CL, White GC 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood. 2009; 113:11–17. PMID: 18820129.

4. Goudemand J. Pharmaco-economic aspects of inhibitor treatment. Eur J Haematol Suppl. 1998; 63:24–27. PMID: 9882929.

5. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012; 119:1335–1344. PMID: 22101900.

6. Mannucci PM. Getting rid of refractory hemophilia. Blood. 2012; 119:1326–1327. PMID: 22323405.

7. Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007; 109:546–551. PMID: 16990605.

8. Ingerslev J, Sorensen B. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol. 2011; 155:256–262. PMID: 21895627.

9. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009; 15:3–10. PMID: 19016901.

10. Han MH, Park YS. Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience. Blood Res. 2013; 48:282–286.